Trial Profile
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 13 Aug 2019 Status changed from active, no longer recruiting to completed.
- 03 Dec 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 03 Dec 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.